[go: up one dir, main page]

WO2001068069A3 - Pharmaceutical composition comprising paracetamol - Google Patents

Pharmaceutical composition comprising paracetamol Download PDF

Info

Publication number
WO2001068069A3
WO2001068069A3 PCT/GB2001/001142 GB0101142W WO0168069A3 WO 2001068069 A3 WO2001068069 A3 WO 2001068069A3 GB 0101142 W GB0101142 W GB 0101142W WO 0168069 A3 WO0168069 A3 WO 0168069A3
Authority
WO
WIPO (PCT)
Prior art keywords
paracetamol
compound
antipyretic
analgesic
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2001/001142
Other languages
French (fr)
Other versions
WO2001068069A2 (en
Inventor
John Anthony Henry
Seif Omar Shaheen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Ip2ipo Innovations Ltd
Original Assignee
Kings College London
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0006301A external-priority patent/GB0006301D0/en
Priority claimed from GB0026716A external-priority patent/GB0026716D0/en
Priority claimed from GB0102462A external-priority patent/GB0102462D0/en
Application filed by Kings College London, Imperial College Innovations Ltd filed Critical Kings College London
Priority to AU40852/01A priority Critical patent/AU4085201A/en
Publication of WO2001068069A2 publication Critical patent/WO2001068069A2/en
Publication of WO2001068069A3 publication Critical patent/WO2001068069A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the use of a paracetamol compound in combination with a glutathione enhancing compound as an analgesic or antipyretic. In particular, the present invention relates to the use of a paracetamol compound and a glutathione enhancing compound for simultaneous, separate or sequential use as an analgesic or antipyretic by a patient suffering from or susceptible to an allergic disease or an inflammatory lung desease. The present invention also relates to the use of a paracetamol compound and a glutathione enhancing compound for simultaneous, separate or sequential use as an analgesic or antipyretic by a pregnant woman to prevent the development of wheezing and/or asthma in the offspring.
PCT/GB2001/001142 2000-03-15 2001-03-15 Pharmaceutical composition comprising paracetamol Ceased WO2001068069A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU40852/01A AU4085201A (en) 2000-03-15 2001-03-15 Pharmaceutical composition

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0006301.6 2000-03-15
GB0006301A GB0006301D0 (en) 2000-03-15 2000-03-15 Pharmaceutical composition
GB0026716A GB0026716D0 (en) 2000-11-01 2000-11-01 Pharmaceutical composition
GB0026716.1 2000-11-01
GB0102462A GB0102462D0 (en) 2001-01-31 2001-01-31 Pharmaceutical composition
GB0102462.9 2001-01-31

Publications (2)

Publication Number Publication Date
WO2001068069A2 WO2001068069A2 (en) 2001-09-20
WO2001068069A3 true WO2001068069A3 (en) 2002-04-11

Family

ID=27255599

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/001142 Ceased WO2001068069A2 (en) 2000-03-15 2001-03-15 Pharmaceutical composition comprising paracetamol

Country Status (2)

Country Link
AU (1) AU4085201A (en)
WO (1) WO2001068069A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951001B2 (en) 2008-05-20 2018-04-24 Acorda Therapeutics, Inc. Hepatoprotectant acetaminophen mutual prodrugs

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1575501A2 (en) * 2002-07-12 2005-09-21 University of Rochester Use of amino acids for treatment of various conditions
DE10360954B3 (en) * 2003-12-23 2005-08-18 Esparma Gmbh Use of silibinin, its salts and / or its prodrugs together with α-lipoic acid for the treatment of chronic obstructive pulmonary diseases
DE102006058183A1 (en) * 2006-11-29 2008-06-05 Eberhard-Karls-Universität Tübingen Universitätsklinikum Use of substances that lower the cellular glutathione content for the manufacture of a medicament for the treatment of T-cell mediated autoimmune diseases
ITMI20080187A1 (en) * 2008-02-07 2009-08-08 Velleja Res Srl AMINO ACID FORMULATIONS FOR THE PREVENTION OF HEPATIC PARACETAMOL DAMAGE
CA2767833C (en) 2009-07-15 2018-10-23 Leland Stanford, The Board Of Trustees Of The Junior University N-acetyl cysteine compositions and methods to improve the therapeutic efficacy of acetaminophen
ES2627409T3 (en) * 2010-12-09 2017-07-28 Maruishi Pharmaceutical Co., Ltd. Acetaminophen Stabilizer
US20140179615A1 (en) * 2012-07-12 2014-06-26 Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd. Glutathione and Acetaminophen Composition and Preparation Method Thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1463505A (en) * 1973-11-21 1977-02-02 Nat Res Dev Pharmaceutical compositions
FR2401906A1 (en) * 1977-09-02 1979-03-30 Aiache Jean Marc Water soluble analgesic salts of paracetamol - with amino acids derived from proteins
WO1994020086A1 (en) * 1993-03-12 1994-09-15 British Technology Group Limited Pharmaceutical compositions comprising paracetamol and l-cysteine or a precursor thereof
GR1002731B (en) * 1996-10-21 1997-07-04 Uni-Pharma ����� ������ �.�.�.�. ������������ ���������� Medicinal solutions containing combinations of paracetamol and other active ingredients
FR2744917A1 (en) * 1996-02-16 1997-08-22 Kouchner Gerard THERAPEUTIC COMPOSITION BASED ON ACETAMINOPHENE
US6159500A (en) * 1996-12-31 2000-12-12 Antioxidant Pharmaceuticals Corporation Pharmaceutical preparations of glutathione and methods of administration thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1463505A (en) * 1973-11-21 1977-02-02 Nat Res Dev Pharmaceutical compositions
FR2401906A1 (en) * 1977-09-02 1979-03-30 Aiache Jean Marc Water soluble analgesic salts of paracetamol - with amino acids derived from proteins
WO1994020086A1 (en) * 1993-03-12 1994-09-15 British Technology Group Limited Pharmaceutical compositions comprising paracetamol and l-cysteine or a precursor thereof
FR2744917A1 (en) * 1996-02-16 1997-08-22 Kouchner Gerard THERAPEUTIC COMPOSITION BASED ON ACETAMINOPHENE
GR1002731B (en) * 1996-10-21 1997-07-04 Uni-Pharma ����� ������ �.�.�.�. ������������ ���������� Medicinal solutions containing combinations of paracetamol and other active ingredients
US6159500A (en) * 1996-12-31 2000-12-12 Antioxidant Pharmaceuticals Corporation Pharmaceutical preparations of glutathione and methods of administration thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUITEMA, A. D. R. (1) ET AL: "A dose-dependent delayed hypersensitivity reaction to acetaminophen after repeated acetaminophen intoxications.", HUMAN & EXPERIMENTAL TOXICOLOGY, (JULY, 1998) VOL. 17, NO. 7, PP. 406-408., XP001051459 *
NUTTALL S.L. ET AL: "Frequent paracetamol use linked to asthma.", LANCET, (6 MAY 2000) 355/9215 (1648-1649)., XP001051414 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951001B2 (en) 2008-05-20 2018-04-24 Acorda Therapeutics, Inc. Hepatoprotectant acetaminophen mutual prodrugs

Also Published As

Publication number Publication date
WO2001068069A2 (en) 2001-09-20
AU4085201A (en) 2001-09-24

Similar Documents

Publication Publication Date Title
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
IL178128A0 (en) Salts of 3-0-(3',3'-dimethyl-succinyl) betulinic acid and pharmaceutical compositions containing the same
WO2006031878A3 (en) Imidazoquinoline compounds
WO2004087153A3 (en) Use of organic compounds for immunopotentiation
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2002047715A3 (en) Compositions of peptide crystals
BR0008699A (en) Combinations of formoterol and demometasone furoate for asthma
WO2004078712A3 (en) Isoquinoline derivatives and methods of use thereof
IL228952B (en) Use of compositions comprising ferric citrate for the preparation of medicaments for reducing serum phosphate levels
WO2004047792A3 (en) Liposomal glucocorticoids
WO2002004421A3 (en) Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
WO2005011614A8 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
WO2006004449A3 (en) A combination composition
WO2001068069A3 (en) Pharmaceutical composition comprising paracetamol
WO2001000566A3 (en) Substituted phenoxyacetic acids
EP1262196A3 (en) Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
WO2004028548A3 (en) Inhibitors of the nitrix oxide synthase iii (nos iii) as neuroprotective agents
WO2006115509A3 (en) Small molecule immunopotentiators and assays for their detection
WO2005079396A3 (en) O,o'-amidomalonate and n,o-amidomalonate platinum complexes
WO2002017894A3 (en) Pharmaceutical formulation of salmeterol and fluticasone propionate
WO2004032975A3 (en) Biphenyls and fluorenes as imaging agents in alzheimer's disease
WO2003020963A3 (en) Proteins in type 2 diabetes
WO2006056696A3 (en) 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP